New combo therapy aims to stop liver cancer in its tracks
NCT ID NCT04996914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a precise, high-dose radiation treatment (SBRT) after a standard procedure (TACE) can better control liver cancer in people whose tumors cannot be surgically removed. About 30 adults with early- or intermediate-stage liver cancer will receive the combination therapy. The main goal is to see if the treated tumor stays under control for at least one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
RWTH Aachen University Hospital
RECRUITINGAachen, North Rhine-Westphalia, 52074, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new imaging agent could tell doctors which liver cancers will resist immunotherapy
- Can adding a fourth drug shrink large liver tumors that invade the portal vein?
- Can a Four-Drug cocktail tame inoperable liver cancer?
- Chemo-loaded microspheres aim to starve liver tumors from within
- New combo therapy aims to shrink liver tumors in Hard-to-Treat patients
- New combo shrinks untouchable liver tumors, opens door to surgery